Transcranial Direct Current Stimulation Combined With Balance Training for Chronic Ankle Instability: A Double-Blind, Pilot Randomized Controlled Trial.

J Sport RehabilMay 5, 2026 (epub)

Joosung Kim, Alan Needle, Jinhyun Lee et al.

✦ AI-curated · Sources linked

In 30 seconds

This double-blind pilot randomized controlled trial evaluated whether active transcranial direct current stimulation (tDCS) added benefit to balance training in 19 individuals with chronic ankle instability. Participants received active or sham stimulation during training over 4 weeks. Static postural control, neural excitability, and self-reported ankle function changed over time in both groups, but the study found no clear added benefit from active tDCS. Estimated group differences were generally small; selected outcomes showed potentially larger effects, including fibularis longus corticospinal excitability (d = -0.88).

Key findings

  • Static balance, soleus corticospinal excitability, and perceived ankle function changed over time regardless of tDCS assignment.
  • Estimated active-versus-sham differences were small for most measures at weeks 2 and 4.
  • Potentially moderate and large effects were observed for eyes-closed center of pressure area (d = -0.62) and fibularis longus corticospinal excitability (d = -0.88), respectively.

Why it matters

The findings suggest that balance training may be accompanied by changes in postural control and ankle function, while adding tDCS did not show a clear overall advantage in this pilot study. The selected outcome signals may help guide further research, but the results are preliminary and do not establish a reliable clinical benefit.

What to keep in mind

The trial was a pilot study with 19 participants, and individual analyses and effect-size estimates limit the certainty of conclusions about group-level benefit.

Source

Published in J Sport Rehabil. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Physical Medicine & Rehabilitation

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.